Allogeneic CD19-Targeting T Cells for Treatment-Refractory Systemic Lupus Erythematosus: A Phase 1 Trial

Scientists developed YTS109, a hypoimmune allogeneic T cell product engineered using CRISPR–Cas9 to knock out TRAC, PD1, HLA-A, HLA-B, and CIITA, with a CD19-targeting synthetic TCR and antigen receptor (STAR) precisely integrated into the TRAC locus to enable physiological, TCR-like signaling.